An artist's impression of the CTTQ Pharma's global research and development headquarters. [Photo/WeChat ID: guojihongqiao]
One of the most innovative and fastest-growing pharmaceutical manufacturers in China — CTTQ Pharma — is rapidly advancing the construction of its global research and development headquarters in the Shanghai Hongqiao International Central Business District.
Launched in April 2023, the project is now over 80 percent complete. It is set to open its doors for business in mid-2026.
The new facility will be a hub for cutting-edge research and drug development. It will feature four advanced labs and five innovation platforms, focusing on areas like bispecific antibodies and advanced drug delivery systems.
The headquarters will serve as a global innovation incubator, helping to design and develop new drugs. It will also act as a bridge for international drugs entering China, using CTTQ's global clinical resources.
Key goals include developing breakthrough drug technologies, especially for cancer treatment — streamlining the path from R&D to the market and enhancing international collaboration, in order to integrate advanced global pharmaceutical technologies.
With its opening, the facility aims to attract top global researchers and to also drive innovation, helping Shanghai become a leading biopharmaceuticals hub.
